All In Biotech

Drug Trial Radar · NCT02031432

CORAL XT - Open-label Extension Trial of the CORAL Trial

An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

76

Actual

Start

Dec 18, 2013

Primary completion

Apr 2016

Study completion May 3, 2016

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. In addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.

Conditions

  • Pain
  • Neoplasms
  • Chronic Pain

Interventions

  • CebranopadolDrug

    Film-coated tablet; strengths: 200, 400, or 600 µg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Event (TEAEs)Time frame: Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow up after the last dose)

Locations

22 sites in 10 countries. Site status is shown where the registry gives one.

  • AT004

    Vienna, Austria

  • BE001

    Sint-Niklaas, Belgium

  • BG001

    Shumen, Bulgaria

  • BG008

    Sofia, Bulgaria

  • BG003

    Sofia, Bulgaria

  • BG004

    Sofia, Bulgaria

  • DK006

    Aalborg, Denmark

  • DK004

    Herlev, Denmark

  • DE008

    Böhlen, Germany

  • DE010

    Munich, Germany

  • HU011

    Nyíregyháza, Hungary

  • PL012

    Będzin, Poland

  • PL014

    Dąbrowa Górnicza, Poland

  • PL003

    Gdansk, Poland

  • PL010

    Gliwice, Poland

  • RO002

    Cluj-Napoca, Romania

  • RS003

    Belgrade, Serbia

  • RS002

    Kamenitz, Serbia

  • RS005

    Zrenjanin, Serbia

  • SK004

    Bratislava, Slovakia

  • SK001

    Prešov, Slovakia

  • SK005

    Pruské, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.